Ashish Bajel

Ashish Bajel

Melbourne, VIC, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 91 publications

Phase 1 clinical trial of S64315, an intravenous MCL1 inhibitor, in patients with myeloid malignancies.

Phase 1 clinical trial of S64315, an intravenous MCL1 inhibitor, in patients with myeloid malignancies.

Journal: Leukemia & lymphoma
Published: July 26, 2026

Neutropenia Duration During AZA-VEN Induction for AML Is Bimodal and Correlates With Infection Risk.

Neutropenia Duration During AZA-VEN Induction for AML Is Bimodal and Correlates With Infection Risk.

Journal: Blood advances
Published: May 05, 2026

Subtherapeutic posaconazole exposure during delayed-release tablet prophylaxis in high-risk patients with haematological malignancies: rationale for routine therapeutic drug monitoring.

Subtherapeutic posaconazole exposure during delayed-release tablet prophylaxis in high-risk patients with haematological malignancies: rationale for routine therapeutic drug monitoring.

Journal: The Journal of antimicrobial chemotherapy
Published: January 29, 2026

Pre-transplant azacitidine does not improve survival in allogeneic HSCT for higher-risk MDS.

Pre-transplant azacitidine does not improve survival in allogeneic HSCT for higher-risk MDS.

Journal: Bone marrow transplantation
Published: December 27, 2025

Rhino-sino-orbital and/or central nervous system infections due to Lomentospora prolificans and Scedosporium spp. in onco-haematology patients.

Rhino-sino-orbital and/or central nervous system infections due to Lomentospora prolificans and Scedosporium spp. in onco-haematology patients.

Journal: Medical mycology
Published: December 26, 2025

Reduced burden of infection with consecutive day dosing of high dose cytarabine consolidation versus conventional dosing for acute myeloid leukemia.

Reduced burden of infection with consecutive day dosing of high dose cytarabine consolidation versus conventional dosing for acute myeloid leukemia.

Journal: Leukemia & lymphoma
Published: December 18, 2025

Consensus guidelines for the subsequent management of neutropenic fever after empiric therapy.

Consensus guidelines for the subsequent management of neutropenic fever after empiric therapy.

Journal: Internal medicine journal
Published: October 16, 2025

Consensus guidelines for initial management of neutropenic fever.

Consensus guidelines for initial management of neutropenic fever.

Journal: Internal medicine journal
Published: October 16, 2025

Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study.

Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study.

Journal: Blood
Published: January 30, 2025

Time to complete remission is an independent determinant of survival after intensive chemotherapy in AML.

Time to complete remission is an independent determinant of survival after intensive chemotherapy in AML.

Journal: Blood
Published: January 27, 2025

Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies.

Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies.

Journal: Blood
Published: January 16, 2025

Dose escalation study of the HLA-A2-WT1 CD3 bispecific antibody RO7283420 in relapsed/refractory acute myeloid leukemia.

Dose escalation study of the HLA-A2-WT1 CD3 bispecific antibody RO7283420 in relapsed/refractory acute myeloid leukemia.

Journal: Blood neoplasia
Published: December 16, 2024
Showing 1-12 of 91

Last Updated: 09/26/2026